On September 27, 2025, the Sino-American Pharmaceutical Professionals Association (SAPA) grandly held the 2025 SAPA Annual Meeting at Hyatt Regency New Brunswick, New Jersey. As SAPA's most influential flagship event, this annual meeting has attracted widespread attention from the Chinese-American pharmaceutical community in North America and has become an annual industry gala. Exclcirc (Suzhou) Biomedical Co., Ltd. is pleased to announce that it actively participated in this annual meeting as a sponsor to contribute to industry exchanges and development.

With the theme of "Grasping the Evolution of the Healthcare Landscape and Exploring New Opportunities in Biomedical Science", the 2025 SAPA Annual Meeting features a plenary keynote speech and seven thematic parallel forums. These forums cover cutting-edge and hot areas such as drug discovery and development, CMC (Chemistry, Manufacturing, and Controls) & outsourcing services, artificial intelligence and data science, AI practical workshops, investment and business development, clinical development and regulatory affairs, as well as career development. Experts, scholars, and industry elites from various fields  gather together to discuss the latest trends and development directions of the pharmaceutical industry.

Exclcirc Biomed's sponsorship not only demonstrates the company's strong support for industry exchange activities but also highlights its determination to actively participate in promoting the innovative development of the biomedical field. By participating in this annual meeting, Exclcirc Biomed conducts in-depth exchanges with various stakeholders in the industry, absorbs cutting-edge concepts and experiences, and further expands the company's R&D ideas and cooperation opportunities. Meanwhile, leveraging the broad platform of the annual meeting, Exclcirc Biomed also showcases its technical strength and innovative achievements in circRNA research and development, enhancing the company's reputation and influence in the industry.

During the annual meeting, team members of Exclcirc Biomed  actively participated in various forums and activities, conduct face-to-face communication and exchanges with participants, share the company's practical experience in the research and development of nucleic acid drugs and protein drugs, and explore potential cooperation possibilities. The entities that Exclcirc Biomed communicated and exchanged with include BMS, J&J, Hengrui Medicine, InnoCare Pharma, Merck , AstraZeneca, Regeneron, CHOP , Axela Biosciences, Biocytogen, Medicilon, Fosun Pharma, MedChemExpress, PharmaLegacy Laboratories, Pharmaron, Protheragen, TRiCBIO, WuXi AppTec, and WuXi XDC etc.

With the support of many enterprises including Exclcirc Biomed, the 2025 SAPA Annual Meeting has brought a feast of knowledge and ideas to the Chinese-American pharmaceutical community in North America, injecting new vitality and impetus into the future development of the industry.